Reading CYCN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CYCN free→Reading CYCN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CYCN free→QuarterlyIQ Insights · CYCN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure. On April 1, 2026, Cyclerion and Korsana issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. Furnished as Exhibit 99.2 hereto and incorporated herein by reference is the investor presentation that wil…
Changes in Control of Registrant. To the extent required by this Item, the information included in
Entry into a Material Definitive Agreement. Merger Agreement On April 1, 2026, Cyclerion Therapeutics, Inc., a Massachusetts corporation (“ Cyclerion ”), Cariboos Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Cyclerion (“ First Merger Sub ”), Cariboos Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Cyclerion (“ Second Merger Sub ” and, together with First Merger Sub, “ Merger Sub ”), and Korsana Biosciences, Inc., a Delaware…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. To the extent required by this Item, the information included in
Entry into a Material Definitive Agreement. On January 3, 2026, Cyclerion Therapeutics, Inc. (the “Company”) and the Medsteer, SAS (“Medsteer”) entered into a Collaboration and Option Agreement (the “Collaboration Agreement”) pursuant to which Medsteer granted to the Company (i) a non-exclusive, worldwide, royalty-free, sublicensable license of certain of Medsteer’s technology, software and intellectual property to develop an anesthetic delivery system with Medsteer and (ii) an exclusive opti…
Regulation FD Disclosure On January 5, 2026, the Company issued a press release announcing its entry into the Collaboration Agreement and providing an update on the development of CYC-126, its lead product candidate. In addition, the Company has prepared an investor presentation with respect to the License Agreement and update on CYC-126. A copy of the press release and investor presentation are attached to this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively, and in…
Other Events On December 1, 2025, Akebia Therapeutics, Inc. (“Akebia”) publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (“FSGS”) using Praliciguat, an oral soluble guanylate cyclase licensed to Akebia by Cyclerion Therapeutics, Inc. (Cyclerion”). Pursuant to the terms of Amendment #1 to the License Agreement by and between Akebia and Cyclerion, upon initiation (defined as first patient dosed) of a Phase 2 clinica…
Entry into a Material Definitive Agreement. On September 19, 2025, Cyclerion Therapeutics, Inc. (the “Company”) and the Massachusetts Institute of Technology (“MIT”) entered into a Patent License Agreement (the “License Agreement”) pursuant to which MIT granted to the Company an exclusive worldwide license to develop and commercialize products using certain technology for the treatment of neuropsychiatric disorders, such as depression, in humans. Under the terms of the License Agreement, the…
Entry into a Material Definitive Agreement. On May 7, 2025, Cyclerion Therapeutics, Inc. (the “Company”) and Guggenheim Securities, LLC (“Guggenheim Securities”) entered into a Sales Agreement (the “Sales Agreement”), pursuant to which the Company may offer and sell shares of common stock, no par value per share (the “Shares”), having an aggregate offering price of up to $20,000,000 from time to time through or to Guggenheim Securities, acting as the Company’s agent, subject to the applicatio…
Unregistered Sales of Equity Securities. The information contained in
Entry into a Material Definitive Agreement. Stock Purchase Agreement On March 21, 2025, Cyclerion Therapeutics, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with the investors named therein, including Peter Hecht and Michael Higgins, who serve as members of the Company’s Board of Directors (each, an “ Investor ” and collectively, the “ Investors ”) for the private placement of 499,998 shares (the “ Shares ”) of the Company’s common stock, no par…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.